Arthritis suppression by NADPH activation operates through an interferon-β pathway by Olofsson, Peter et al.
BioMed  Central
Page 1 of 19
(page number not for citation purposes)
BMC Biology
Open Access Research article
Arthritis suppression by NADPH activation operates through an 
interferon-β pathway
Peter Olofsson*1, Annika Nerstedt1, Malin Hultqvist2, Elisabeth C Nilsson1, 
Sofia Andersson1, Anna Bergelin1 and Rikard Holmdahl2
Address: 1Biovitrum AB, Arvid Wallgrens Backe 20, SE-413 46 Göteborg, Sweden and 2Medical Inflammation Research, I11 BMC, Lund University, 
SE-221 84 Lund, Sweden
Email: Peter Olofsson* - peter.olofsson@biovitrum.com; Annika Nerstedt - annika.nerstedt@biovitrum.com; 
Malin Hultqvist - malin.hultqvist@med.lu.se; Elisabeth C Nilsson - elisabeth.nilsson@biovitrum.com; 
Sofia Andersson - b01sofan@student.his.se; Anna Bergelin - anna.bergelin@astrazeneca.com; Rikard Holmdahl -r i k a r d . h o l m d a hl@med.lu.se
* Corresponding author    
Abstract
Background: A polymorphism in the activating component of the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase complex, neutrophil cytosolic factor 1 (NCF1), has previously been
identified as a regulator of arthritis severity in mice and rats. This discovery resulted in a search for
NADPH oxidase-activating substances as a potential new approach to treat autoimmune disorders such
as rheumatoid arthritis (RA). We have recently shown that compounds inducing NCF1-dependent
oxidative burst, e.g. phytol, have a strong ameliorating effect on arthritis in rats. However, the underlying
molecular mechanism is still not clearly understood. The aim of this study was to use gene-expression
profiling to understand the protective effect against arthritis of activation of NADPH oxidase in the
immune system.
Results: Subcutaneous administration of phytol leads to an accumulation of the compound in the inguinal
lymph nodes, with peak levels being reached approximately 10 days after administration. Hence, global
gene-expression profiling on inguinal lymph nodes was performed 10 days after the induction of pristane-
induced arthritis (PIA) and phytol administration. The differentially expressed genes could be divided into
two pathways, consisting of genes regulated by different interferons. IFN-γ regulated the pathway
associated with arthritis development, whereas IFN-β regulated the pathway associated with disease
protection through phytol. Importantly, these two molecular pathways were also confirmed to
differentiate between the arthritis-susceptible dark agouti (DA) rat, (with an Ncf-1DA allele that allows only
low oxidative burst), and the arthritis-protected DA.Ncf-1E3 rat (with an Ncf1E3 allele that allows a stronger
oxidative burst).
Conclusion: Naturally occurring genetic polymorphisms in the Ncf-1 gene modulate the activity of the
NADPH oxidase complex, which strongly regulates the severity of arthritis. We now show that the Ncf-
1  allele that enhances oxidative burst and protects against arthritis is operating through an IFN-β-
associated pathway, whereas the arthritis-driving allele operates through an IFN-γ-associated pathway.
Treatment of arthritis-susceptible rats with an NADPH oxidase-activating substance, phytol, protects
against arthritis. Interestingly, the treatment led to a restoration of the oxidative-burst effect and induction
of a strikingly similar IFN-β-dependent pathway, as seen with the disease-protective Ncf1 polymorphism.
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Background
Rheumatoid arthritis (RA) is one of the commonest
autoimmune diseases, with a prevalence of 0.5–1% [1,2].
RA is a chronic and severely disabling disease of unknown
etiology, although both environmental [3] and genetic
factors [4] are believed to play roles in its cause. There is
presently no cure for RA, although a variety of different
drugs is used to treat the symptoms. The most common
treatments include disease-modifying antirheumatic
drugs such as,methotrexate [5,6]. Other efficient antirheu-
matic drugs are the recently developed biological-
response modifiers, such as tumor necrosis factor (TNF)-
α blockers, which reduce both the established inflamma-
tion and joint destruction [7]. The drawback of these treat-
ments is an increased risk of infections because the body's
defense system is impaired. Other biological-response
modifiers targeting other cytokines or costimulatory mol-
ecules are currently being clinically tested and evaluated
[8]. Despite this range of antirheumatic drugs, there is still
a large number of RA patients for whom none of these
treatments is effective [9,10], thus making the develop-
ment of new therapies essential.
Identification of new targets for development of antirheu-
matic drugs is hampered by the heterogeneity of RA and
the complexity of its molecular pathology. However,
recent efforts with linkage-association studies, both in
human populations and in animal models, are now giv-
ing results in the form of successful identification of
autoimmunity-regulating genes [11-15]. The combined
results from such studies will eventually lead to a greater
understanding of the molecular regulation of this com-
plex disease and they present potential new targets for
drug development.
Neutrophil cytosolic factor 1 (Ncf1), also known as p47phox,
was one of the first single genes identified to regulate
arthritis severity. This finding was a result of linkage anal-
ysis and positional cloning in an arthritis model in rats
using a cross between the arthritis-susceptible dark agouti
(DA) rat and the arthritis-resistant E3 strains
DA.Ncf1E3([14,16]. NCF-1 is the activating component of
the NADPH oxidase complex, which, upon activation,
produces reactive oxygen species (ROS) [17]. We found
that the dramatic increase in arthritis severity was caused
by a decreased capacity of the nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase complex to pro-
duce ROS. Interestingly, the lower oxidative burst led to a
reduction in cell membrane proteins and activation of
autoreactive and arthritogenic T cells [18]. Thus, the iden-
tified Ncf1 polymorphism and its effect on the immune
system by decreased ROS production was concluded to be
associated with the regulation of arthritogenic CD4 T cells
in the immune priming phase [14,19].
NADPH oxidase-activating substances such as phytol
(3,7,11,15-tetramethyl-2-hexadecene-1-ol), were identi-
fied from studies performed on a human neutrophil cell
line, and have subsequently been shown to be very effica-
cious in the treatment of arthritis in rats [20]. However,
the mechanism through which these compounds act is
still not completely understood.
The intention of this study was to obtain a molecular
insight into the anti-inflammatory mechanism of NADPH
oxidase activation by phytol in an experimental arthritis
model in rats, the pristane-induced arthritis (PIA) model
[21]. To analyze the in vivo effects of the NADPH oxidase
activator phytol versus the effects of the arthritis-inducing
compound pristane, global gene-expression profiling was
performed. A biodistribution analysis of phytol was per-
formed to determine which tissue and time point would
be most relevant to investigate. Phytol was observed to
accumulate slowly in inguinal lymph nodes, with peak
levels being reached approximately 11 days after subcuta-
neous administration, which coincides with the onset
period of arthritis. In the global gene-expression profiling,
inguinal lymph nodes obtained 10 days after administra-
tion were analyzed. This analysis revealed several genes
that were differentially expressed in rats with PIA com-
pared with rats injected with phytol. A group of interesting
genes was selected and verified by quantitative real-time
PCR analysis in three further separate biological experi-
ments, including a comparative study between the DA
and DA.Ncf1E3 congenic rats. The comparison between
the two strains was aimed at determining whether the
selected genes were differentially expressed in the arthri-
tis-susceptible DA rat versus the arthritis-resistant con-
genic DA.Ncf1E3 rat. Such data would indicate whether the
NADPH oxidase-activating compound phytol is activating
a pathway that is normally inactive in the absence of a
fully functional Ncf1.
By studying gene-expression profiles and performing
pathway analysis, we have identified the importance of an
IFN-β-dependent pathway as one molecular mechanism
for the arthritis-ameliorating efficacy of NADPH oxidase-
activating compounds.
Results
The discovery that NADPH oxidase-derived ROS have dis-
ease-protecting effects in arthritis opens up new possibili-
ties for drug development against autoimmune and
inflammatory diseases. To obtain a more detailed under-
standing of the molecular mechanism of this regulation,
gene-expression profiling experiments were performed on
inguinal lymph nodes from rats with pharmacologically
(phytol) and genetically (Ncf1) modified NADPH oxidase
activity.BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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Biodistribution and NADPH oxidase activation
Phytol has previously been identified as a potent NADPH
oxidase activator [14,20]. The in vivo distribution of phy-
tol was analyzed and examined by subcutaneous injection
of tritium-labeled phytol into the base of the tail in DA
rats. The rats were killed and dissected 2, 4, 8, 11 and 17
days after administration. Various organs (inguinal lymph
nodes, spleen, heart, thymus, kidney, liver, lung, fat, mus-
cle and peripheral blood) were collected, homogenized
and analyzed in a beta counter to determine tissue-incor-
porated tritiated phytol. Most of the administered phytol
remained as a depot at the injection site (> 90%, data not
shown), whereas phytol distributed to tissues was recov-
ered mainly from the inguinal lymph nodes. Furthermore,
the accumulation of phytol in the lymph nodes reached
its maximum level 11 days after administration (Figure 1).
No phytol was detected in peripheral blood at the time
points studied or in blood collected at earlier time points
(2, 6, 13 or 25 hours after administration, data not
shown). Further analysis of the biodistribution of phytol
at the microscopic level in the inguinal lymph nodes was
performed by microautoradiography. It was shown that
phytol was distributed primarily to the cortical regions
and also in the sinusoidal space of the inguinal lymph
nodes (data not shown). Moreover, the staining seemed
to appear between cells or in the cell membrane, but not
intracellularly.
Global gene-expression profiling
Previous results have shown that the NADPH oxidase acti-
vator phytol has ameliorating properties on arthritis when
administrated prior to arthritis induction and when given
as therapeutic treatment [20]. To obtain a molecular
understanding of the protective effects of phytol on PIA,
four groups of animals were subjected to different condi-
tions; (i) induced arthritis by injection with pristane, (ii)
injection with phytol, (iii) injection with both pristane
and phytol, and (iv) no treatment. All animals were killed
close to disease onset, i.e.10 days after administration.
Global gene-expression profiling using chip arrays (Gene-
chip®;Affymetrix, Santa Clara, CA, USA) was performed
on the collected inguinal lymph nodes from the described
animals. The gene-expression pattern was quite different
between treated rats and naïve controls. Comparing any
of the group of treated animals and untreated animals, >
350 differentially expressed genes were detected (at signif-
icance level p < 0.05 and absolute fold change > 1.4; data
not shown). However, as the most interesting differences
were to be found between the different treatments, the
analysis focused on these groups. When comparing phy-
tol-treated versus pristane-treated animals, the expression
of 29 genes was significantly changed (p < 0.05, with abso-
lute fold change > 1.4). Of these 29 genes, 13 showed
expression in phytol-treated rats, whereas 16 genes
showed higher expression in pristane-treated rats (Figure
2). Because more complex gene induction was observed in
animals given phytol plus pristane, further studies con-
centrated on analyses of single-compound administra-
tions.
Quantitative real-time PCR validation of differentially 
expressed genes
To minimize erroneous conclusions due to technical vari-
ability and multiple testing effects inherent to the micro-
array technology, as well as biological variation,
quantitative real-time PCR analysis was used to validate
expression profiles of nine differentially expressed genes
(Table 1) in separate biological material. This verification
confirmed all examined transcripts to be differentially
expressed (data not shown). In addition, there was strong
correlation between the fold changes detected using glo-
bal gene expression and the quantitative real-time PCR
analysis for the identified genes (Table 1; Pearson correla-
tion coefficient R2 > 0.96) [22].
The genes upregulated by injections with pristane were Ass, Cxcl9 
and Mmp12
Ass  (argininosuccinate synthetase) encodes an enzyme
involved in the urea cycle mediating the condensation of
citrulline and aspartic acid to form arginine. The expres-
sion of Ass  is induced by common pro-inflammatory
cytokines (interleukin (IL)-1β, interferon (IFN)-γ and
TNF-α) [23,24]. CXCL9 (Chemokine (C–X–C motif) lig-
and 9, also known as Mig, (monokine induced by IFN-γ))
is a chemokine belonging to the CXC subfamily of chem-
okines acting through G-protein-coupled receptors [25].
These proteins have chemoattraction and growth-promot-
ing properties and are induced by IFN-γ and, to some
extent, TNF-α to attract T cells to sites of inflammation
[26]. Higher levels of CXCL9 expression have been
observed in the synovial tissues and fluids of patients with
RA compared with tissues and fluids from control patients
[27]. MMP12 (matrix metalloproteinase 12) belongs to
the family of matrix metalloproteinases (MMPs) [28],
which are involved in cell migration and degradation of
cartilage and bone by remodeling the extracellular matrix.
Inducers of expression of MMPs include IL-1β, TNF-α [29]
and IFN-γ [30]. Abnormal levels of MMPs have been
found in patients with autoimmune disorders such as RA
and multiple sclerosis [31].
The genes upregulated by phytol were Best5, Irf7, Ifit3, Oas1, Mx2 
and S100a9
Best5 (bone-expressed sequence tag 5) is mainly
expressed in bone marrow and spleen and has been pro-
posed to be involved in bone formation. The cytokines
IFN-α and IFN-γ have been shown to induce BEST5
expression in osteoblasts [32].Interferon regulatory factor
(IRF)-7 belongs to the IRF family of transcription factors
involved in cell growth, antiviral defense and immuneBMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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activation in lymphoid cells in spleen, thymus, and
peripheral blood [33,34]. IRF7 is part of the pathway acti-
vated by viral infection to induce the production of IFN
type I (IFNtα/β) by a positive feedback loop [35]. IRF7
was recently reported to be the master regulator of IFN
type I-dependent immune responses [36], and recent pub-
lications have shown that an IRF5 polymorphism is
strongly associated with systemic lupus erythematosus
(SLE) [37,38]. Interferon-induced protein with tetratr-
icopeptide repeats (IFIT)-3 is induced by IFN-α [39] and
IFN-β but not IFN-γ [40]. However, IRF-7 most probably
has a dual role, being both a strong regulator of IFN
expression [35] and being induced by IFN in a positive
feedback regulation [35,41].
The protein 2',5'-oligoadenylate synthetase (OAS)-1
belongs to the OAS family, which was one of the first
groups of IFN-induced antiviral proteins to be character-
ized. The activation of this mechanism is induced by the
IFN type I pathway, which is activated upon pathogenic
invasion as part of an antiviral response [42].
Myxovirus resistance (MX)-2 has a functional role in the
defense against viral infections and its expression is partly
Tissue distribution of tritium-labeled phytol in rats. Biodistribution was estimated as relative counts per minute per gram of tis- sue Figure 1
Tissue distribution of tritium-labeled phytol in rats. Biodistribution was estimated as relative counts per 
minute per gram of tissue. A large fraction of phytol remained as a depot in the injection site (> 90%, not shown). Besides 
that, the inguinal lymph nodes were the primary tissue for accumulation of phytol. The distribution of phytol to the inguinal 
lymph nodes showed the highest accumulation > 1 week after injection and showed a reduction after 2 weeks. Values are 
means from groups of four animals.
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controlled by type I IFNs [43]. MX2 is induced by type I
IFNs, and to a less extent by IFN-γ and lipopolysaccharide
[44].
S100a9 is a small calcium-binding protein that belongs to
the S100 family. It is primarily expressed by neutrophils
but also by activated monocytes and macrophages [45].
S100a9 has been shown to have a chemoattractant func-
tion in inflamed tissue, attracting neutrophils and induc-
ing the adhesion of the attracted cells [46]. Elevated levels
of S100a9 have been found in the synovial fluid [47] and
plasma [48] of patients with RA.
Identification of interferon-regulated pathways
To find a connection between the differentially expressed
genes bioinformatic tools (Ingenuity Pathway Analysis;
Ingenuity systems Inc., CA, USA, and PathwayAssist; Strat-
agene, CA, USA) and literature studies were used to assign
pathways for these genes. Using these analysis tools, large
schematic diagrams, covering all published interactions
Hierarchical clustering of differentially expressed genes in phytol-treated compared with pristane-treated rats Figure 2
Hierarchical clustering of differentially expressed genes in phytol-treated compared with pristane-treated rats. 
Euclidean distance was used as a similarity measure. Each column represents one individual rat, and each horizontal stripe rep-
resents a gene transcript. The Affymetrix probe set identification, the gene symbol, the average fold change (FC) for phytol 
versus pristane together with the p value, and the average fold change for phytol/pristane versus pristane and its p value are 
given to the right. The colors in the clustering represent the gene-expression level in each individual rat compared with the 
average expression in all arrays, where green indicates low expression and red represents high expression.
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between the identified genes and common denominators,
are produced. However, in this study we chose to focus on
and validate one common denominator for the regulation
of the identified differentially expressed genes, i.e.Ifn
types I and type II (Ifnγ) [35,49]. In addition, this stratifi-
cation of the bioinformatic information was performed to
make it possible to verify these findings using quantitative
real-time PCR and to validate the biological importance of
the identified pathway in further biological experiments.
Hence, the identified central pathways for further studies
included the genes increased in expression due to treat-
ment with pristane (Ass, Cxcl9 and Mmp12), which are reg-
ulated by Ifn-γ and genes with increased expression due to
phytol (Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9), which
are induced by IFN-α/β.
Both IFN-α/β and IFN-γ have an important role in the
immunological response to pathogens and viruses. How-
ever, type I IFNs are mainly produced by plasmacytoid
dendritic cells [50], whereas IFN-γ is produced by macro-
phages, natural killer (NK) cells and activated T helper
(Th) cells. Consequently, the Ifn genes were included in
the panel of genes to be further studied.
Time study
To analyze how the expression of the selected genes (Table
1) varies over time, a third biological experiment was per-
formed. In this experiment, only pristane-treated or
phyto- treated animals were studied, and inguinal lymph
nodes were isolated at 0, 3, 6, 8, 10, 13, 15 and 19 days
after injection. This time study enabled us to follow the
expression of these genes during the development of
arthritis induced by pristane (Figure 3).
The three genes associated with increased expression after
pristane administration (Ass, Cxcl9 and Mmp12) showed
significantly increased expression (p < 0.01) after disease
onset (i.e. days 13–19 after pristane administration) com-
pared with the phytol-treated group. Phytol induced a
small increase in expression of these genes around the day
of disease onset (day 8–13) and then decreased to the
same low expression as seen at day 0 (Figure 4). The fact
that the highest expression of these genes occurs after
arthritis onset makes it plausible that the increased expres-
sion of these genes is associated with the inflammatory
response. However, as seen for the expression of Cxcl9
(Figure 4B), which also increased significantly (p < 0.05)
at days 3–6 after pristane injection, the expression of such
genes also plays a role in the early response after injection.
All genes associated with increased expression after phytol
administration (Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9)
showed significantly increased expression (p < 0.05) com-
pared with pristane (Figure 5) in the early disease-onset
period (day 8–10). The expression levels then decreased
to the same low level as for the pristane-treated rats.
Besides the genes described above, S100a8 and the Mx2-
related gene Mx1 were also analyzed in this time study
and shown to be expressed in a similar pattern to that of
S100a9 and Mx2, respectively (data not shown). As these
genes are closely related, only one of each was followed
for further expression characterization. The expression of
Ncf1 was also included in this analysis as a control. How-
ever, no marked difference in Ncf1  expression was
detected between the groups of animals (data not shown).
The expressions of the Ifn genes were also analyzed over
time (Figure 6). The expression of Ifnγ was significantly
increased in the rats injected with pristane (p < 0.01) and
expression of Ifnα and Ifnβ was increased after injection
with phytol. To further validate the significance of the
increased expression of Ifnα and Ifnβ in DA rats at day 10
after treatment with phytol, RNA samples produced from
all four separate experiments was analyzed for Ifnα and
Ifnβ expression levels in DA rats treated with either pris-
tane (n = 19) or phytol (n = 18). This combined dataset
showed an upregulation of IFN-α (p < 0.05) and an upreg-
Table 1: Differentially expressed genes selected for further studies of the mechanism involved in pristane-induced arthritis and 
treatment with phytol.
Gene name UniGene ID number Protein Fold change* p
Best5 Rn.14882 Bone-expressed sequence tag 5 2.17 0.005
Irf7 Rn.101159 Interferon regulatory factor 7 1.75 0.005
Ifit3 Rn.35775 Interferon-induced protein with tetratricopeptide repeats 3 2.22 0.008
Oas1 Rn.10383 2',5'-oligoadenylate synthetase 1 1.69 0.01
Mx2 Rn.10374 Myxovirus (influenza virus) resistance 2 1.70 0.02
S100a9 Rn.6703 Calcium binding protein a9 3.60 0.007
Ass Rn.5078 Argininosuccinate synthetase - 3.24 0.0009
Mmp12 Rn.33193 Matrix metalloproteinase 12 - 3.82 0.0007
Cxcl9 Rn.7391 Chemokine (C-X-C motif) ligand 9 - 1.86 0.004
The genes were chosen based on the difference in expression levels between phytol and pristane treatment in the Affymetrix Genechip® analysis.
*Phytol versus pristane.BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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ulation of IFN-β (p < 0.01) in phytol-treated compared
with pristane-treated animals. The increased expression of
Ifnα/β coincided with the most pronounced increase in
expression of Best5, Irf7, Ifit3, Oas1, Mx2 and S100a9, i.e.
day 8–10 after treatment (Figure 5 and Figure 6A, B).
Hence, Ifnα and Ifnβ could be postulated to be common
regulatory genes for this molecular pathway of genes that
were all induced by phytol treatment. However, it should
be noted that the expression levels of the studied type I
interferons were very low and that the difference in
expression levels could only be detected using quantita-
tive real-time PCR (Figures 6 and 9).
TNF-α and IL-1 are other cytokines identified as impor-
tant immunological regulators in the same molecular
pathways as the interferons. Transcription of Tnfα and IL-
1 is increased in macrophages activated by IFN-α to act
synergistically with IFN-γ in initiating a chronic inflam-
matory response. The expression of Tnfα and IL-1 was also
analyzed, but only a small decrease in the expression of
Tnfα could be observed after phytol administration, and
the expression of IL-1 was below the detection limit (data
not shown).
Verification of Ifn type I pathway in Ncf1 congenic rats
The selected genes that were identified as being associated
with either the disease state (pristane) or treatment state
(phytol) of DA rats, were further analyzed in another bio-
logical experiment including a comparison between DA
and congenic DA.Ncf1E3 rats. These rats carry different
alleles of the Ncf1 gene, and differ dramatically in arthritis
severity; the DA rat is highly susceptible and the congenic
DA.Ncf1E3 is almost completely resistant to arthritis [14].
This analysis was included to study the importance of the
selected genes for the difference in arthritis susceptibility
caused by different Ncf1 alleles, and thus also NADPH
oxidase functionality in PIA compared with phytol treat-
ment. Administration with either pristane or phytol leads
to increased expression of Ass, Cxcl9 and Mmp-12 in both
strains, compared with the untreated controls (p < 0.01)
(Figure 7). Further, a clear and significant difference (p <
0.001) between the pristane-treated and phytol-treated
animals was observed, although no significant difference
was found between the two rat strains.
Expression of Best5, Irf7, Ifit3, Mx2, Oas1 and S100a9 were
all induced by phytol, compared with untreated controls
(p < 0.01). Interestingly, after pristane injection, there was
significantly higher expression (p < 0.05) of Best5, Irf7,
Ifit3 and Mx2 in DA.Ncf1E3 rats than in DA rats. No differ-
ence in expression levels between the strains was observed
for S100a9. Overall, the gene expression of Best5, Irf7,
Ifit3, Mx2 and Oas1 showed the highest expression levels
in rats that had been injected with a combination of pris-
tane and phytol (Figure 8).
Ifnα was expressed at a lower level in both the pristane-
treated and phytol-treated animals, and in the rats with
combined treatment, compared with the untreated con-
trol rats (p < 0.01) (Figure 9A). The expression of Ifnβ was
significantly higher (p < 0.01) in the pristane-injected or
phytol-injected groups than in the untreated control
group, while the combined treatment induced even
higher expression (Figure 9B). The expression of Ifnγ was
significantly higher (p < 0.01) for the rats injected with
pristane than for both control and phytol-treated rats (Fig-
ure 9C). Interestingly, only Ifnβ showed different expres-
sion in the DA.Ncf1E3 rats compared with DA rats after
pristane injection (p < 0.05). The expression level of Ifnβ
in DA rats after pristane injection was comparable with
that of untreated control rats; however, after phytol
administration, the level of Ifnβ was increased to a level
equal to that of DA.Ncf1E3 rats (Figure 9B).
Cell distribution in Ncf1 congenic rats
The levels of different cell populations in the studied tis-
sue may affect the outcome of gene-expression profiling.
Therefore, fluorescence-activated cell-sorting (flow
cytometry, BD Biosciences) analyses were performed on
Arthritis development in rats after subcutaneous administra- tion of pristane (circles) or phytol (squares) in the time study  experiment Figure 3
Arthritis development in rats after subcutaneous 
administration of pristane (circles) or phytol 
(squares) in the time study experiment. Only animals 
injected with pristane developed arthritis. Values are means 
± SEM from groups of four animals. Levels of significance 
were calculated using Student's t-test (***p < 0.001).
0
5
10
15
20
25
30
35
40
0 5 10 15 20
Pristane
Phytol
a
r
t
h
r
i
t
i
s
 
s
e
v
e
r
i
t
y
day after injection
***BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
Page 8 of 19
(page number not for citation purposes)
isolated inguinal lymph nodes to determine whether the
observed differentially expressed genes could be
explained by a skewed cell population. In both the pris-
tane-treated and phytol-treated rats, the number of B and
NK cells were raised compared with untreated controls,
whereas the relative number of T cells were lower. Signifi-
cantly more B and NK cells were observed after phytol
treatment than after pristane treatment (p < 0.01, DA and
DA.Ncf1E3 combined). No significant alterations in the
subset of cells containing macrophages and dendritic cell
populations (i.e. CD4+TCR- cells) could be detected (data
not shown). No difference between the strains was
observed for all of the studied groups of animals (Figure
10). These effects on cell populations could have a major
impact on the gene-expression profiles, but as no differ-
ence between the strains was observed, the differentially
expressed genes assigned to the Ifnβ pathway are unlikely
to be the result of differences in these cell populations.
Discussion
Ncf1 is a gene encoding the activating component of the
NADPH oxidase complex. By positional cloning in rat
models of arthritis, a polymorphism of Ncf1 was found to
regulate arthritis severity [14]. In fact, it was shown that a
less functional Ncf1, and the resulting decrease in NADPH
oxidase capacity to produce ROS, is a major cause of
increased arthritis severity in both rat and mouse models
of arthritis, an observation that challenges the general
dogma of the inflammatory role of ROS. Furthermore,
NADPH-activating substances have both preventive and
therapeutic effects on arthritis, which opens up new
approaches for disease treatment [20]. However, from the
results of the positional cloning of Ncf1  and the data
showing strong ameliorating effects of ROS-inducing
compounds in animal models, we are still a long way
from fully understanding the underlying mechanism of
action.
One approach to obtaining a molecular insight into a
complex biological system is to use global gene-expres-
sion profiling [51]. An advantage of this method is the
large set of genes that can be analyzed in the same experi-
mental setup, making it possible to use clustering and
pathway analysis of large sets of genes [52,53]. The assem-
bled biological information can then be stratified into
molecular pathways that can be studied and thoroughly
validated.
However, the intricate choice of time point and tissue/cell
type to be selected for analysis presents a significant hur-
dle [54]. A further difficulty is the need for biological rep-
licates and the genetic heterogeneity that is involved in
human studies. This has naturally led to some skepticism
regarding the utility of gene-expression profiling as a
method to achieve an understanding of rheumatic dis-
The relative mRNA expression of (A) Ass, (B) Cxcl9 and (C)  Mmp12 in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days  after injection with pristane (circles) or phytol (squares) Figure 4
The relative mRNA expression of (A) Ass, (B) Cxcl9 
and (C) Mmp12 in lymph nodes at 0, 3, 6, 8, 10, 13, 15 
and 19 days after injection with pristane (circles) or 
phytol (squares). Values are means ± SEM from groups of 
four animals. Levels of significance were calculated using Stu-
dent's t-test (*p < 0.05; **p < 0.01; ***p < 0.001).BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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eases [55]. However, recent analysis of gene-expression
fingerprints of individual patients with RA might give
hope for this still technically evolving method for under-
standing complex disorders [56-59].
In this study, we used global gene-expression analysis and
quantitative real-time PCR techniques in four separate
arthritis experiments in rats to investigate the downstream
effects of preventive arthritis treatment with the NADPH
oxidase activator phytol. Based on biodistribution analy-
ses of phytol after SC administration, global gene-expres-
sion analysis was performed on inguinal lymph nodes at
a time point just before the estimated day of disease onset.
We observed that the expression of our set of differentially
expressed genes in our material varies dramatically during
the disease progress (Figures 4, 5, 6). Therefore, it is nec-
essary to have information about which time point and
tissue to analyze before initiating gene-expression profil-
ing. Furthermore, we also analyzed, in other tissues (i.e.
thymus, blood and spleen) the expression of the genes
identified as differentially expressed in inguinal lymph
nodes, and observed that the expression levels could be
quite different or even undetectable in these tissues (data
not shown). As a result, it is not possible to extrapolate the
information between tissues and time points. In addition,
the number of biological replicates used in the compared
groups should be high enough to enable statistical analy-
sis. Altogether, these issues make these studies extremely
cumbersome to perform, especially when analyzing
human samples. By using animal models, a more opti-
mized study design may be provided [60], as a number of
identical (inbred) individuals under the same treatment
and environmental conditions are compared and tissue
collected at the same time point by the same researcher.
In this study, we identified a molecular mechanism that
links the protective effects observed from treatment with
NADPH oxidase activators with a relevant inflammatory
mechanism. However, it is not the differentially expressed
genes per se that are most interesting, but the molecular
pathways that can be extracted (Figure 11). From our
comparison between pristane (arthritis inducer [21]) and
The relative mRNA expression of (A) Best5, (B) Irf7, (C) Ifit3, (D) Oas1, (E) Mx2 and (F) S100a9 in lymph nodes at 0, 3, 6, 8, 10,  13, 15 and 19 days after injection with pristane (circles) or phytol (squares) Figure 5
The relative mRNA expression of (A) Best5, (B) Irf7, (C) Ifit3, (D) Oas1, (E) Mx2 and (F) S100a9 in lymph nodes 
at 0, 3, 6, 8, 10, 13, 15 and 19 days after injection with pristane (circles) or phytol (squares). Values are means ± 
SEM from groups of four animals. Levels of significance were calculated using Student's t-test (*p < 0.05; **p < 0.01).BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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Gene-expression comparison between DA (open bars) and  DA. Ncf1E3 (filled bars) of (A) Ass, (B) Cxcl9, and (C) Mmp12  in inguinal lymph nodes 10 days after injection Figure 7
Gene-expression comparison between DA (open 
bars) and DA. Ncf1E3 (filled bars) of (A) Ass, (B) Cxcl9, 
and (C) Mmp12 in inguinal lymph nodes 10 days after 
injection. Values are means ± SEM of 4–5 animals per 
group. No significant difference between the strains was 
detected.
The relative mRNA expression of (A) Ifnα, (B) Ifnβ and (C)  Ifnγ in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 19 days after  injection with pristane (circles) or phytol (squares) Figure 6
The relative mRNA expression of (A) Ifnα, (B) Ifnβ 
and (C) Ifnγ in lymph nodes at 0, 3, 6, 8, 10, 13, 15 and 
19 days after injection with pristane (circles) or phy-
tol (squares). Values are means ± SEM from groups of four 
animals. Levels of significance were calculated using Student's 
t-test (**p < 0.01).BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
Page 11 of 19
(page number not for citation purposes)
phytol (NADPH oxidase-activating and arthritis-amelio-
rating compound [20]), two main pathways were identi-
fied. The pristane-induced pathway was marked by
increased expression of Ass, Cxcl9 and Mmp12 (Table 1).
These genes all share IFN-γ as a common regulator
[30,61,62], which was also shown to be upregulated in
the inguinal lymph nodes, in a similar pattern, after
induction of arthritis with pristane (Figures 4, 6C, 7 and
9C). IFN-γ is known to effect the balance between Th1 and
Th2 cells, and increased expression of this pro-inflamma-
tory cytokine plays an important role in the progression of
RA [63]. Although pristane stimulates the expression of
these cytokine-regulated genes, no direct conclusions
about whether these genes are involved in the cause of
arthritis can be drawn, as no difference in gene expression
could be seen between the arthritis-susceptible strain
(DA) and the arthritis-protected strain (DA.Ncf1E3) (Fig-
ures 7 and 9C). As the DA.Ncf1E3 congenic rats carry the
arthritis-protecting variant of Ncf1, one might speculate
that the effect caused by the functional Ncf1 is to generate
a resistance to the effect from induction of Ass, Cxcl9 and
Mmp12 genes, which might otherwise contribute to the
development of arthritis. Further investigation of the
effect on disease regulation is needed to be able to pro-
pose a more exact role for these genes as potential markers
of arthritis [64].
Six genes (Best5, Irf7, Ifit3, Mx2, Oas1 and S100a9) were
identified as genes induced by phytol (Table 1). The com-
mon inducers of these are IFN-α and IFN-β. These interfer-
ons are anti-inflammatory cytokines expressed after
pathogenic infections [35,65,66]. From the gene-expres-
sion data it is not possible to determine whether IRF-7 is
upregulated by an increased level of IFN-α/β as a down-
stream feedback regulator of the IFN-α/β receptor or if
increased IFN-β level is the result of an upregulation of
IRF-7 [35,41,36]. Oas1 and Mx2 are both induced upon
viral invasion and IFN type I activation, and are thus reg-
ulated by the same pathway [67]. The expression of Best5
can be induced by both IFN-α/β and IFN-γ, but studies
have shown IFN-α/β to have the strongest enhancing
effect on the expression [32].
Gene-expression comparison between DA (open bars) and DA. Ncf1E3 (filled bars) of (A) Best5, (B) Irf7, (C) Ifit3, (D) Oas1, (E)  Mx2 and (F) S100a9 in inguinal lymph nodes 10 days after injection Figure 8
Gene-expression comparison between DA (open bars) and DA. Ncf1E3 (filled bars) of (A) Best5, (B) Irf7, (C) 
Ifit3, (D) Oas1, (E) Mx2 and (F) S100a9 in inguinal lymph nodes 10 days after injection. Values are means ± SEM of 
4–5 animals per group. Levels of significance between the strains were calculated using Student's t-test (*p < 0.05).BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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Gene-expression comparison between DA (open bars) and  DA. Ncf1E3 (filled bars) of (A) Ifnα, (B) Ifnβ and (C) Ifnγ in  inguinal lymph nodes 10 days after injection Figure 9
Gene-expression comparison between DA (open 
bars) and DA. Ncf1E3 (filled bars) of (A) Ifnα, (B) Ifnβ 
and (C) Ifnγ in inguinal lymph nodes 10 days after 
injection. Values are means ± SEM of 4–5 animals per 
group. Levels of significance between the strains were calcu-
lated using Student's t-test (*p < 0.05).
Relative (%) number of lymphocytes Figure 10
Relative (%) number of lymphocytes. Comparison 
between DA (open bars) and DA.Ncf1E3 (filled bars) of (A) B 
cells, (B) T cells and (C) NK cells in inguinal lymph nodes 10 
days after treatment injection. Values are means ± SEM of 4–
5 animals per group. No significant difference between the 
strains was detected.BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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Interestingly, a clear tendency in the expression of Ifnβ
between DA and DA.Ncf1E3 strains was observed after
injection with pristane, with the DA.Ncf1E3 rats having
higher expression of Ifnβ than the DA rats (Figure 9B).
This difference in expression level clearly resembles the
differences observed for the phytol-induced genes Best5,
Irf7, Ifit3, Mx2 and Oas1 (Figure 8). It is therefore likely
that the downstream effect of the polymorphism in Ncf1,
as well as the therapeutic effect of phytol, involves regula-
tion of an IFN-β pathway. This IFN-β-regulated gene pro-
file is interesting with respect to similarities to the patterns
that have been identified in patients with SLE and in
patients with juvenile arthritis treated with anti-TNF-α
[68-71], and in mouse models of SLE [72]. Subpopula-
tions with active RA have also been shown to express
increased levels of Ifn type I signature genes in peripheral
blood [59]. These reports show an Ifnα/β expression sig-
nature, which is very similar to that identified in the rats
treated with phytol. However, in our study, the Ifn type I
expression profile was linked to disease protection while
the SLE Ifn type I profile was linked to disease progression.
This may indicate that the interferon balance could be an
important threshold denominator of autoimmune dis-
eases, functioning as an essential balance for immune reg-
ulation, with an imbalance resulting in either SLE or
arthritis. This is also exemplified by a recent study in
which pristane was used to induce SLE in mice. In that
study, chronic peritoneal administration of pristane elic-
ited increased expression of the type I interferon-inducible
genes Mx1, Irf7, IP-10 and Isg-15 as a consequence of SLE
[72]. However, despite the similarities in expression pat-
tern, it must be noted that the SLE studies were performed
on tissues other than inguinal lymph nodes and on estab-
lished disease, so that differences in gene profiles could be
caused by tissue differences or time-dependent regulation.
Also interesting is the fact that the present study points
towards a disease-ameliorating pathway that is regulated
by IFN-β. Therefore, as the present observation of
increased Ifn type I signature genes was observed to be a
signal for prevention of disease onset, in contrast to the
studies in ongoing SLE [68]and arthritis [59], one might
speculate that increased IFN type I regulation is a way to
downregulate an ongoing immune response. Such an
attempt to limit the inflammatory response has been sug-
gested previously [73], and has also been indicated by
experiments in our laboratory using Ifnβ-deficient mice,
Schematic representation of the differentially expressed genes and how they are induced upon injection by (A) pristane or (B)  phytol Figure 11
Schematic representation of the differentially expressed genes and how they are induced upon injection by (A) 
pristane or (B) phytol. The molecular pathway that is shared between the arthritis resistant DA.Ncf1E3 rat strain and the 
arthritis treatment achieved with phytol is the Ifn-β-dependent pathway, which results in the upregulation of Best5, Irf7, Ifit3, 
Oas1 and Mx2. The inflammatory arthritis that is induced by an injection with pristane is characterized by increased expression 
of the Ifnγ-connected signature genes Ass, Cxcl9 and Mmp12, which potentially could be used as molecular markers for an initi-
ating inflammatory response. As this pathway is also induced by pristane in the DA.Ncf1E3 strain this upregulation per se does 
not cause arthritis. Most important in this mechanism is how administration of phytol induces arthritis protection via the Ifn-β-
regulated pathway in the arthritis-susceptible DA rats.
Pristane
DA.Ncf1
E3 rats DA rats
Ifnγ Ifnβ
Ass, Mig, Mmp12 Best5, Irf7, Ifit3
Mx2, Oas1
Arthritis Healthy
Phytol
DA.Ncf1
E3 rats DA rats
Ifnβ
Best5, Irf7, Ifit3
Mx2, Oas1
Healthy
Ifnγ
Ass, Mig, Mmp12
Ifnβ
Best5, Irf7, Ifit3
Mx2, Oas1
Healthy
ABBMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
Page 14 of 19
(page number not for citation purposes)
where a prolonged arthritis severity was observed due to
Ifnβ deficiency [74]. In fact, treatment with recombinant
IFN-β significantly reduces cartilage destruction and bone
destruction in collagen-induced arthritis in mice, which
suggested a beneficial effect in patients also [70]. How-
ever, to date no positive outcome of clinical trials using
recombinant IFN-β in RA has been presented [75,76]. As
we have shown that the effect of phytol on Ifnβ-related
genes is time-dependent and also correlates with the bio-
distribution of phytol to the inguinal lymph nodes, it is
possible that tissue distribution as well as the dose and
frequency of administration are crucial for the efficacy of
arthritis treatment via this pathway.
The data presented here, together with gene-expression
profiles of SLE, [68-71] and arthritis [59] strongly suggests
the importance of the IFN-α/β pathway as a key mecha-
nism in autoimmune conditions [77].
The fact that no difference in cell populations was
observed to explain the differential levels of mRNA for
IFN-β-regulated genes does not prove that alterations in
cell populations in the inguinal lymph nodes are not cru-
cial. As IFN-β is mainly produced by plasmacytoid den-
dritic cells [77], which were not specifically addressed in
this study, more careful analysis of this cell population
might provide further insight into the disease-protecting
effects of phytol in arthritis.
Increased expression of S100a9  was observed in rats
treated with phytol (Figure 5F). However, the expression
of S100a9 did not show any difference between DA and
DA.Ncf1E3 rats (Figure 8F), and the expression profile was
not similar to that of Ifnβ (Figure 9B). As a result, we con-
sider S100a9 not to be regulated by IFN-β. It is more likely
that the increased levels of S100a9 expression is a direct
effect of increased concentrations of intracellular Ca2+
induced by the NADPH oxidase-produced ROS [78,79].
Increased expression of S100a9 is mostly reported to be
proinflammatory. However, this knowledge is based on
analyses from tissues and blood during ongoing inflam-
mation, while these studies analyzed inguinal lymph
nodes prior to disease onset. Hence, the expression levels
for different timepoints of the disease process could differ.
Table 2: Primers used for the quantitative real-time PCR.
UniGene Gene name FP/RP Sequence (5'-3')
Rn.1079 Arbp FP AGAGTCGGAGGAATCCGATGA
RP AAGCAGGCTGACTTGGTGTGA
Rn.38575 Ncf1 FP CGAGAGTGGCTGGTGGTT
RP CATACGGTTCACCTGCGTAGT
Rn.5078 Ass FP TGTTCGCCACTGCATCGA
RP TGGCCCTTGAAGACAGATACCT
Rn.7391 Cxcl9 FP ACGGAGATCAAACCTGCCTAGAC
RP CATCAGCTTCTTCACCCTTGCT
Rn.33193 Mmp12 FP AGGTACGATGTGAGGCAGGAA
RP TCCTGGGAAGTGTGTAGAAATCAG
Rn.14882 Best5 FP TCATTCTGCGTTGGAGTTTGG
RP CTGAATTATTGATGGGAGGAGTCA
Rn.101159 IRF7 FP CAGAACCCCAACTTCCAATAGAGT
RP TAGAGATGACATATAGCCAAGGAATAAGC
Rn.35775 Ifit3 FP TGGGAGGCAACACGATTTG
RP TGACACACTTCCGGTTGTTATCAG
Rn.10383 Oas1 FP GGATCACAGTCCATGCTTCTGA
RP CTGTGATTGGACAGTATTCAAACATG
Rn.10374 Mx2 FP GTGACACCAGTGAGAAGAGGAGATT
RP GCTAGCCTGCGCTGAGCTT
Rn.6703 S100a9 FP TGGACACAAACCAGGACAATCA
RP CTCATGACAGGCAAAGATCAACTT
Rn.143194 Ifnα 1 FP GCAACCCTCCTAGACTCATTCTG
RP ACCCCTACCTGCTGCATCAG
Rn.138105 Ifnβ 1 FP CTTGGGTGACATCCACGACTAC
RP GGCATAGCTGTTGTACTTCTTGTCTT
Rn.10795 Ifnγ FP AATCGCACCTGATCACTAACTTCTT
RP TGGGTTGTTCACCTCGAACTT
The final concentration of each primer in the sample was 400 nM, except for Ifnβ 1, for which 800 nM was used.
FP, forward primer; RP, reverse primer.BMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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Even so, S100a9 may be a good biomarker for the in vivo
efficacy of administered phytol as an activator of NADPH
oxidase specifically in lymph node tissues.
Conclusion
By targeting the NADPH oxidase complex with activating
compounds such as phytol, we highlight a new mecha-
nism to treat autoimmune conditions such as arthritis. By
extracting and verifying a relevant biological molecular
mechanism from gene-expression profiling data, we also
indicate a plausible relation between increased levels of
ROS and an anti-inflammatory response regulated by an
IFN-β pathway. The use of gene-expression profiling to
compare treatments in animal models of complex dis-
eases also points to a useful pharmacogenomic approach
to extract relevant information about the mechanism of
action and to identify potential molecular biomarkers to
be used in future animal experiments and clinical trials.
Methods
Animals
DA rats used in the microarray analysis, the first verifying
quantitative real-time PCR study, the time study and the
biodistribution study were purchased from Harlan Neth-
erlands, and the DA.Ncf1E3 rats with background origin
from Zentralinstitut Für Versuchstierzucht, Hannover,
Germany [80,81]. All animals were kept in a climate-con-
trolled environment with 12-hour light/dark cycles,
housed in polystyrene cages containing wood shavings
and fed standard rodent chow and water ad libitum. The
rats were free from common pathogens including Sendai
virus, Hantaan virus, coronavirus, reovirus, cytomegalovi-
rus and Mycoplasma pulmonalis. The experiments were
approved by the local ethics committees (Göteborg,
Swedish license 230/2003 and Malmö/Lund, Swedish
license M70/2004).
Induction and evaluation of arthritis
Pristane (Sigma-Aldrich, St. Louis, MO, USA) and/or phy-
tol (3,7,11,15-tetramethyl-2-hexadecene-1-ol) (Sigma-
Aldrich) were injected into the rats (age 8–12 weeks) by a
single subcutaneous injection of 200 μL at the base of the
tail. Arthritis development was monitored with a macro-
scopic scoring system of the four limbs ranging from 0 to
15 (1 point for each swollen or red toe, 1 point for mid-
foot digit or knuckle, 5 points for a swollen ankle). The
scores of the four paws were added, yielding a maximum
total score of 60 for each rat [82].
In the global gene-expression profiling and the first verify-
ing quantitative real-time PCR experiment, five rats per
group were used. In the comparative experiment between
the DA and the DA.Ncf1E3 strain, 4–5 rats per group were
used. In all three experiments, the analyzed groups were;
naïve controls, pristane-treated, phytol-treated and pris-
tane plus phytol-treated animals. All rats were killed 10
days after injection. In the time-resolution study for com-
parison between pristane and phytol, four animals from
each group were killed at 0, 3, 6, 8, 10, 13, 15 and 19 days
after injection. The inguinal lymph nodes were immedi-
ately surgically removed and stored in a tissue-storage rea-
gent (RNA later; Qiagen, Germany).
Biodistribution
DA rats were injected with 200 μL phytol (Sigma-Aldrich)
mixed with tritiated phytol (Moravek Biochemicals, CA,
USA) to a final dose of 167 μCi/rat. The rats, four each
day, were killed at 2, 4, 8, 11 or 17 days after injection,
and the inguinal lymph nodes, spleen, heart, thymus, kid-
ney, liver, lung, adipose tissue, muscle, injection-site tis-
sue and blood were collected in equal amounts of saline
solution (blood samples had heparin added to prevent
coagulation) in pre-weighed tubes. The tissues were
weighed, homogenized, and mixed with ready-safe scin-
tillation liquid (Beckman Coulter, CA, USA). Tissue distri-
bution of phytol was determined as counts per minute
(cpm) of tritium using a beta counter (LKB Wallac, Turku,
Finland) and cpm/g tissue was determined as the relative
distribution of phytol. Microautoradiography was per-
formed on three individual rats 10 days after subcutane-
ous administration with tritiated phytol (167 μCi/rat).
The inguinal lymph nodes were snap-frozen in liquid
nitrogen and shipped on dry ice to Quest Pharmaceutical
Services (Newark, DE, USA). The frozen lymph nodes
were embedded in optimum cutting temperature (OCT)
embedding media (VWR international, Bristol, CT, USA)
for cryosectioning. Sections of 10 μm thickness were
heated at 50°C for 10 minutes, coated with photographic
emulsion (Kodak NTB; Kodak, New Haven, CT, USA) and
dried. The coated slides were exposed at 4°C in lightproof
boxes. The exposed slides were stained with hematoxylin
and eosin and developed for tritium labeling.
Flow cytometry analysis
Single-cell suspensions were made from inguinal lymph
nodes and cells were stained with the anti-rat antibodies
OX-1 (anti-LCA, lymphocytes), OX-33 (anti-CD45RA, B-
cells), and R73 (anti-αβTCR, T cells) (all BD Pharmingen,
San Diego, CA, USA), and with 3.2.3 (anti-NKRP1, NK
cells, produced from an in-house hybridoma) for 30 min-
utes at 4°C. After washing with phosphate-buffered saline
(PBS), cells were resuspended in PBS and analyzed in a
FACSorter (Becton Dickinson, San Jose, CA, USA). Gates
were set for the relevant cell type and analysed as percent-
age of total lymphocytes.
RNA isolation
Total RNA from inguinal lymph nodes was isolated using
a commercial kit (RNeasy® Mini Kit; Qiagen, Germany).
The protocol for animal tissues was followed with theBMC Biology 2007, 5:19 http://www.biomedcentral.com/1741-7007/5/19
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addition of the optional DNase digestion (RNase-Free
DNase Set; Qiagen). The RNA yield was quantified spec-
trophotometrically (RNA 6000 Nano assay Kit;Agilent
Technologies, Palo Alto, CA, USA) and the quality ana-
lyzed (2100 Bioanalyzer; Agilent). The average ratio
between 28S/18S rRNA was 2.2, indicating high RNA
quality. All RNA and cDNA samples were stored at -80°C.
Preparation of cRNA, hybridization and data analysis
In total, 10 μg of total RNA spiked with poly-A controls
(pGIBS-TRP, pGIBS-THR, and pGIBS-LYS; American Type
Culture Collection) was converted to cDNA, using a T7
promoter-polyT primer (Affymetrix, Santa Clara, CA,
USA) and the reverse transcriptase Superscript II (Invitro-
gen, Paisley, UK), followed by a second-strand cDNA syn-
thesis (Invitrogen). Double- stranded cDNA was in vitro
transcribed to biotinylated cRNA (IVT labelling kit;
Affymetrix) and then fragmented. The fragmented cRNA
was mixed with hybridization spike controls (oligonucle-
otide B2 and a cRNA cocktail: BioB, BioC, BioD, and Cre;
Affymetrix,). Aliquots of each sample were hybridized (16
hours at 45°C) to an array (GeneChip® Rat Expression Set
230A arrays; Affymetrix). The arrays were subsequently
washed, stained and scanned according the manufac-
turer's instructions (GeneChip® Expression Analysis Tech-
nical Manual; Affymetrix). The data were analyzed using
specific sofware (Robust Multi-Chip Analysis in GeneTraf-
fic® UNO version 3.2–11; Stratagene, La Jolla, CA, USA,
and Spotfire DecisionSite for Functional Genomics, ver-
sion 8.1;Spotfire Inc., Göteborg, Sweden). The intensities
were log2 transformed and the mean log2 intensity for
each group calculated. The mean log2 fold change was cal-
culated for the phytol-treated animals versus the pristane-
treated animals by subtracting the mean log2 intensity for
the pristane-treated rats from that for the phytol-treated
rats. The total number of probe sets in the used rat Affyme-
trix chips was 15 923, and the average present call was
45%. Statistical significance of the difference in gene
expression was determined using the two-sided Student's
t-test. A transcript was considered differentially expressed
if the mean absolute fold change was > 1.4 and the p value
< 0.05. In addition, the mean intensity in the group show-
ing the highest expression should be > 75. The average
log2 fold change between the animals treated with phytol
plus pristane versus the animals treated with pristane
alone and the corresponding statistical analysis were also
calculated, although these data were not used to identify
differentially expressed genes.
Accession numbers
The global gene-expression profiling data is deposited on-
line [ArrayExpress: E-MEXP-78].
Quantitative real-time PCR
The primers used in the quantitative real-time PCR were
designed using software (Primer Express 2.1; Applied Bio-
systems, Foster City, CA, USA) and the sequences are
listed in Table 2. Total RNA (5 μg) was transcribed to
cDNA using a commercial system (SuperScript™ First
Strand Synthesis System; Invitrogen). The PCR reaction
was performed in a 25 μL volume including 1 × SYBR®
Green (Applied Biosystems) and 400 nM of each primer,
except for Infβ, for which 800 nM of each primer was used.
All reactions were performed in duplicate, amplified and
quantified (ABI 7000 Sequence Detection System;
Applied Biosystems). The relative quantities of mRNA
were calculated according to the standard curve method
[83] and Arbp (alias 36B4), was used as endogenous con-
trol [84].
Statistics
Quantitative data is expressed as mean ± SEM and signifi-
cance analysis was performed using two-sided Student's T-
test. * Represents a significance value of * p < 0.05, ** p <
0.01 and *** p < 0.001.
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